Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1117

Shown on this page

Current sort

Live official records

Conditions: Myelofibrosis (MF)
Interventions: Navitoclax, Ruxolitinib, Best Available Therapy (BAT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 41
States / cities: Chandler, Arizona • Springdale, Arkansas • Duarte, California + 34 more

Conditions: Kidney Stone, Normal Controls
Interventions: Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Darolutamide, Physician choice Androgen Deprivation (Hormone) Therapy; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Solid Tumor, Adult
Interventions: CRB-701, Anti-PD-1; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • San Diego, California + 12 more

Conditions: Chronic Pain
Interventions: Spinal cord stimulation (SCS), Dorsal root ganglion stimulation (DRG); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Timeline: 2019 – 2029
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Larkspur, California + 24 more

Conditions: DVT
Interventions: IVC filter removal; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Epilepsy, Temporal Lobe
Interventions: NRTX-1001; Biological
Lead sponsor: Neurona Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 17
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 14 more

Conditions: Breast Cancer
Interventions: Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment; Drug · Procedure · Other + 1 more
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more

Conditions: Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
Interventions: Olaparib; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more

Conditions: AML With Gene Mutations
Interventions: ZE46-0134; Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 9 more

Conditions: Urinary Incontinence, Delivery Complication
Interventions: Interventionist-guided training, Home pelvic floor exercises guided by the leva® device, Education; Other · Device
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: San Diego, California • Chicago, Illinois • Durham, North Carolina + 3 more

Conditions: Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
Interventions: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 680
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more

About this University of Chicago Medicine institution page

What this page lists: ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Chicago Medicine

Filter and sort this campus

Live official records

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Oxalate and Citrate

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator

Forceps vs. Snare IVC Filter Removal

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Olaparib In Metastatic Breast Cancer

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

Training for Urinary Leakage Improvement After Pregnancy

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

About this University of Chicago Medicine institution page